Press Releases
InspireMD Appoints Acclaimed Interventional Cardiologist Kenneth Rosenfield, MD as Chair of its Newly Formed Scientific Advisory Board
Tel Aviv, Israel – April 29, 2021 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, today announces the formation of its Scientific Advisory Board with its newly appointed chair, acclaimed interventional cardiologist, Kenneth Rosenfield, M.D. The Company intends… Read More
InspireMD Provides Corporate Update for Shareholders
Tel Aviv, Israel— April 19, 2021 – InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today provided an update of recent corporate developments. Shareholders approved a 1:15 reverse stock split, reducing the number… Read More
InspireMD Announces 1-for-15 Reverse Stock Split
 Tel Aviv, Israel— April 14, 2021 – InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced a 1-for-15 reverse split of its common stock, effective as of April 26, 2021. Beginning on April… Read More
InspireMD CEO Marvin Slosman Issues Letter to Fellow Stockholders Urging Support of the Company’s Plans to List its Common Stock on Nasdaq at the Upcoming Special Meeting of Stockholders
Tel Aviv, Israel – March 22, 2021 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, today issues a message to stockholders from InspireMD CEO, Marvin Slosman regarding the Company’s Special Meeting of Stockholders. To our valued Stockholders: We… Read More
We Are Contacting You as a Reminder of a Critical Shareholder Vote. InspireMD Inc. Urges Shareholders to Vote FOR Reverse Stock Split Proposal
VOTE NOW BY CALLING KINGSDALE ADVISORS AT 1-866-581-1479.or collect at 1-416-867-2272 AND ONE OF OUR AGENTS WOULD BE HAPPY TO TAKE YOUR VOTE OVER THE PHONE. Dear InspireMD Inc. (NSPR) Holdings Shareholder:  You should have already received proxy material related to InspireMD Inc.’s special shareholder meeting on March 17, 2021. AMONG THE PROPOSALS SHAREHOLDERS… Read More
InspireMD Announces Fourth Quarter and Year-End 2020 Financial Results
Management to host investor conference call today, March 9, at 8:30am ET Tel Aviv, Israel— March 9, 2021 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced financial and operating results for the fourth… Read More
InspireMD to Report Fourth Quarter and Year-End 2020 Financial Results on Tuesday, March 9, 2021 and Provide Corporate Update
Earnings conference call to be held Tuesday, March 9, 2021 at 8:30 a.m. ET Tel Aviv, Israel — March 2, 2021 – InspireMD, Inc. (NYSE American: NSPR) (“InspireMD” or the “Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces it… Read More
InspireMD Engages Hart Clinical Consultants to Conduct Clinical Trial for CGuard Carotid Stent System in the United States
Tel Aviv, Israel – February 24, 2021 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it has engaged Hart Clinical Consultants (HCC), a leading Contract Research Organization (CRO) to conduct the clinical trial for its CGuard… Read More
InspireMD Appoints Leading Interventional Cardiologist Chris Metzger, M.D. as Principal Investigator for CGuard Registration Trial in the United States
Tel Aviv, Israel – February 9, 2021 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, announced today the appointment of Chris Metzger, M.D., system chair of clinical research at Ballad Health System in Eastern Tennessee as the principal… Read More
INSPIREMD ANNOUNCES CLOSING OF AN UPSIZED $20.7 MILLION UNDERWRITTEN PUBLIC OFFERING AND FULL EXERCISE OF OVER-ALLOTMENT OPTION
Tel Aviv, Israel, Feb. 08, 2021 (GLOBE NEWSWIRE) — InspireMD, Inc. (“InspireMD”) (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet™ stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East and Asia, today announced the closing of an upsized underwritten public… Read More